<DOC>
	<DOCNO>NCT00306878</DOCNO>
	<brief_summary>The purpose clinical research study determine safety , pharmacokinetics , immunogenicity human , recovery time require biologic effect optimal biologic dose range BMS188667 ( CTLA4Ig )</brief_summary>
	<brief_title>Phase I Study BMS-188667 ( CTLA4Ig ) Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men woman receive adequate counseling judge reliabel use contraceptive measure . Diagnosis documentation stable psoriasis vulgaris least 6 month duration . Psoriasis vulgaris total body surface area involvement 10 % 49 % ( Overall Disease Severity Score [ ODSS ] 47 inclusive ) . Failure toxicity inefficacy least one standard antipsoriatic therapy include topical treatment , etretinate , phototherapy , methotrexate . Treatment : ) Retinoids within 2 year , b ) cyclosporin A , systemic corticosteroid , methotrexate , investigational agent within 16 week , c ) phototherapy photochemotherapy within 4 week ) topical psoriasis treatment emollient within 2 week prior enrollment . No clinical response prior adequate therapeutic trial cyclosporin A Prolonged exposure sun within 4 week prior first dose . Guttate , erythrodermic , pustular psoriasis . Spontaneously improve rapidly deteriorate psoriasis vulgaris .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>